| General Information | |
|---|---|
| ZINC ID | ZINC000049746303 |
| Molecular Weight (Da) | 558 |
| SMILES | N#CCc1c(C(=O)NCc2ccc(F)c(Br)c2)nn(-c2ccccc2Cl)c1-c1ccc(Cl)cc1 |
| Molecular Formula | C25Br1Cl2F1N4O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 136.484 |
| HBA | 3 |
| HBD | 1 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 34 |
| LogP | 6.949 |
| Activity (Ki) in nM | 0.7079 |
| Polar Surface Area (PSA) | 70.71 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.156 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 23 |
| Fraction csp3 | 0.08 |
| Ilogp | 4.52 |
| Xlogp3 | 6.36 |
| Wlogp | 7.01 |
| Mlogp | 5.05 |
| Silicos-it log p | 6.86 |
| Consensus log p | 5.96 |
| Esol log s | -7.35 |
| Esol solubility (mg/ml) | 0.0000251 |
| Esol solubility (mol/l) | 0.00000004 |
| Esol class | Poorly sol |
| Ali log s | -7.64 |
| Ali solubility (mg/ml) | 0.0000129 |
| Ali solubility (mol/l) | 2.31E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -10.97 |
| Silicos-it solubility (mg/ml) | 5.95E-09 |
| Silicos-it solubility (mol/l) | 1.07E-11 |
| Silicos-it class | Insoluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.19 |
| Lipinski number of violations | 2 |
| Ghose number of violations | 3 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.17 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.33 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -7.43 |
| Logd | 4.518 |
| Logp | 5.791 |
| F (20%) | 0.001 |
| F (30%) | 0.002 |
| Mdck | - |
| Ppb | 99.04% |
| Vdss | 0.808 |
| Fu | 1.56% |
| Cyp1a2-inh | 0.386 |
| Cyp1a2-sub | 0.138 |
| Cyp2c19-inh | 0.9 |
| Cyp2c19-sub | 0.066 |
| Cl | 2.723 |
| T12 | 0.039 |
| H-ht | 0.21 |
| Dili | 0.97 |
| Roa | 0.857 |
| Fdamdd | 0.897 |
| Skinsen | 0.031 |
| Ec | 0.003 |
| Ei | 0.008 |
| Respiratory | 0.411 |
| Bcf | 2.328 |
| Igc50 | 5.115 |
| Lc50 | 6.953 |
| Lc50dm | 6.628 |
| Nr-ar | 0.017 |
| Nr-ar-lbd | 0.332 |
| Nr-ahr | 0.722 |
| Nr-aromatase | 0.917 |
| Nr-er | 0.577 |
| Nr-er-lbd | 0.019 |
| Nr-ppar-gamma | 0.872 |
| Sr-are | 0.829 |
| Sr-atad5 | 0.161 |
| Sr-hse | 0.373 |
| Sr-mmp | 0.915 |
| Sr-p53 | 0.946 |
| Vol | 478.37 |
| Dense | 1.162 |
| Flex | 0.28 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.285 |
| Synth | 2.539 |
| Fsp3 | 0.08 |
| Mce-18 | 24 |
| Natural product-likeness | -1.748 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |